Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972658 · ClinicalTrials.gov registry record · Phase 3
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT02972658 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 421 participants.
The verdict
NCT02972658, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
Interventions
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972658
The ClinicalTrials.gov registry entry for NCT02972658 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanabecestat is the first listed.
NCT02972658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02972658 about?
NCT02972658 is a clinical study titled "A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia". This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
What is the current status of trial NCT02972658?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2017-03-15. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT02972658?
The interventions under investigation include: Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02972658?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.